Firing up the cold tumors by targeting Vps34
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC..
Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration. In our recent report published in Science Advances, we demonstrate that targeting the autophagy-related protein Vps34 switched cold immune desert tumors into hot inflamed immune-infiltrated tumors and enhanced the efficacy of anti-PD-1/PD-L1. Our study provides the preclinical rationale to set up combination immunotherapy clinical trials using selective Vps34 inhibitors and immune checkpoint blockers in melanoma and CRC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Oncoimmunology - 9(2020), 1 vom: 31. Aug., Seite 1809936 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Janji, Bassam [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.07.2021 Date Revised 28.07.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/2162402X.2020.1809936 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315108738 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM315108738 | ||
003 | DE-627 | ||
005 | 20231226201917.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/2162402X.2020.1809936 |2 doi | |
028 | 5 | 2 | |a pubmed24n1050.xml |
035 | |a (DE-627)NLM315108738 | ||
035 | |a (NLM)32939326 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Janji, Bassam |e verfasserin |4 aut | |
245 | 1 | 0 | |a Firing up the cold tumors by targeting Vps34 |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.07.2021 | ||
500 | |a Date Revised 28.07.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. | ||
520 | |a Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration. In our recent report published in Science Advances, we demonstrate that targeting the autophagy-related protein Vps34 switched cold immune desert tumors into hot inflamed immune-infiltrated tumors and enhanced the efficacy of anti-PD-1/PD-L1. Our study provides the preclinical rationale to set up combination immunotherapy clinical trials using selective Vps34 inhibitors and immune checkpoint blockers in melanoma and CRC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 4 | |a Autophagy | |
650 | 4 | |a CCL5 | |
650 | 4 | |a CXCL10 | |
650 | 4 | |a NK cells | |
650 | 4 | |a T CD8 lymphocytes | |
650 | 4 | |a VPS34 | |
650 | 4 | |a anti-PD-1/PD-L1 | |
650 | 4 | |a cancer immunotherapy | |
650 | 4 | |a cold/hot tumors | |
650 | 4 | |a colon cancer | |
650 | 4 | |a immune landscape | |
650 | 4 | |a melanoma | |
650 | 4 | |a proinflammatory cytokines | |
650 | 7 | |a Autophagy-Related Proteins |2 NLM | |
650 | 7 | |a Immunologic Factors |2 NLM | |
700 | 1 | |a Hasmim, Meriem |e verfasserin |4 aut | |
700 | 1 | |a Parpal, Santiago |e verfasserin |4 aut | |
700 | 1 | |a Berchem, Guy |e verfasserin |4 aut | |
700 | 1 | |a Noman, Muhammad Zaeem |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Oncoimmunology |d 2012 |g 9(2020), 1 vom: 31. Aug., Seite 1809936 |w (DE-627)NLM218817029 |x 2162-402X |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2020 |g number:1 |g day:31 |g month:08 |g pages:1809936 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/2162402X.2020.1809936 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2020 |e 1 |b 31 |c 08 |h 1809936 |